Tevogen Bio secures $50m financing for ExacTcell platform expansion and clinical trials.
Tevogen Bio, a clinical-stage specialty immunotherapy firm, has secured up to $50m in financing to expand its ExacTcell platform for additional clinical trials. The funding will support the company's focus on its initial product, TVGN 489, and further clinical development for virally induced cancers and multiple sclerosis. The financing consists of a $36m line of credit and a $14m private placement at a 30% discount.
May 10, 2024
4 Articles